BOSTON, June 30, 2025 /PRNewswire/ — TOBY, Inc., a biotech startup advancing non-invasive cancer detection through urine-based volatilomics and Artificial Intelligence, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its TOBY Test for Bladder Cancer.
The approach collects multiple types of imaging and sequencing data from the same cells, leading to new insights into mouse liver biology.
A collaboration of leading Chinese research institutions has developed an artificial intelligence-based method called GRAPE, demonstrating high accuracy in detecting gastric cancer from routine noncontrast CT scans.
A Caltech-led team has developed a safe, effective, and painless breast imaging technique that incorporates machine learning to help differentiate between suspicious and healthy tissue.
Mouse models are central to drug development, including treatments for neurological disorders, such as Parkinson’s disease. Such diseases often affect movement, and treatments may need to relieve symptoms such as tremors.